Navigation Links
Cytopia Appoints Study Chairman for JAK2 Clinical Trial
Date:7/29/2008

MELBOURNE, Australia, July 29 /PRNewswire-FirstCall/ -- Cytopia Limited (ASX: CYT) has appointed Dr. Ayalew Tefferi, Professor of Medicine and Hematology at the Mayo Clinic College of Medicine, as Clinical Study Chair for the company's Phase I/II study in patients with myelofibrosis.

Dr. Tefferi is a world-renowned expert in the treatment of myeloproliferative disorders (MPDs) and has authored over 500 research publications and given many hundreds of invited lectures in haematology. He also serves on the editorial boards of a number of leading haematology journals.

Myelofibrosis patients suffer a bone marrow disorder in which the marrow is replaced by fibrous scar tissue. Patients will be treated in this study with Cytopia's novel orally available compound CYT387. This drug inhibits the mutant JAK2 enzyme to specifically treat haematological malignancies, including myelofibrosis.

Many of these particular diseases can lead to life threatening conditions such as leukemia. There are currently no effective long term treatments for these conditions.

"Cytopia is delighted that a clinician of Dr. Tefferi's standing has agreed to chair our Phase I/II program," said Mr. Andrew Macdonald, CEO. "Dr. Tefferi and our other clinical investigators will study and document the clinical benefits of using this highly promising JAK2 inhibitor to treat these blood disorders."

Following the completion of very encouraging in-vivo studies at Oregon Health and Science University early in the year, CYT387 has been undergoing rigorous IND-enabling toxicology studies in recent months. It is anticipated that an Investigational New Drug application will be lodged with the US Food and Drug Administration by the end of the year to support studies in Australia and the United States.

About JAK2

The discovery of a specific single activating mutation in the JAK2 enzyme in MPDs in 2005 has focused attention on developing a therapy for these diseases through selective inhibition of JAK2. To successfully address these chronic diseases with a JAK2 inhibitor, the specificity and resultant tolerability profile is a key element of the product profile required for a "best in class" inhibitor.

Cytopia is a world leader in JAK2 kinase chemistry and holds a broad range of JAK2 related patents. The main area of focus for the JAK2 program has been the development of orally available JAK2 inhibitors to treat myeloproliferative disorders, which include myelofibrosis, polycythemia vera (PV) and essential thrombocythemia (ET) CYT387 is a specific JAK2 inhibitor with excellent potential for safe and efficacious chronic human dosing. It has been derived from Cytopia's knowledge of basic biology of JAK kinases, a strong structural biology program that has delivered multiple co-crystal structures of JAK2 complexed with inhibitors, and the subsequent development of an extensive chemical library of JAK2 inhibitors through an integrated computational and medicinal chemistry platform.

Cytopia is developing a suite of JAK2 inhibitors for multiple indications including the treatment of certain cancers, particularly lymphomas and solid tumours where JAK2 has been shown to be upregulated, and for cardiovascular diseases such as pulmonary hypertension.

About Cytopia

Cytopia Ltd is an Australian biotechnology company focused on the discovery and development of new drugs to treat cancer and other diseases. Cytopia conducts its research and drug development through subsidiaries based in Melbourne, Australia and San Francisco, USA and specializes in developing new small molecule compounds with an improved therapeutic profile for the treatment of cancer.

The lead program for the company is CYT997, a vascular disrupting agent (VDA) for the treatment of various cancers, and currently being trialed in Phase 1 and Phase 2 clinical studies. Cytopia also is building on its range of JAK inhibitors and kinase expertise, with CYT387, a novel oral JAK2 inhibitor focused on the treatment of myeloproliferative disorders, expected to enter Phase 1 clinical studies in early 2009.

Website: http://www.cytopia.com.au


'/>"/>
SOURCE Cytopia Limited
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Cytopia Nominates JAK2 Clinical Candidate for Myeloproliferative Disorders
2. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
3. Release of Cytopia Abstract for CYT997 Oral Presentation at American Society of Clinical Oncology
4. Quark Pharmaceuticals Appoints New Chief Medical Officer
5. West Pharmaceutical Services, Inc. Appoints New Director
6. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
7. Curemark Appoints Preeminent Pediatrics Gastroenterologist
8. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
11. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2017)... --  CerSci Therapeutics , a non-opioid drug development firm ... received notice from the National Institute on Drug Abuse ... it has been awarded a Direct-to-Phase II Small Business ... with an additional $1,000,000 to follow in 2018. These ... their lead non-opioid drug candidate CT-044 to the Food ...
(Date:7/31/2017)... -- 7D Surgical, developer of ground breaking surgical navigation technologies, ... System to support its strategic sales plan in ... Virginia.  7D Surgical has entered into an exclusive sales representative ... facilities within those markets. ... Spartan Medical Purchases 7D ...
(Date:7/27/2017)... July 27, 2017  Zimmer Biomet Holdings, Inc. (NYSE ... ended June 30, 2017.  The Company reported second quarter ... over the prior year period, and an increase of ... basis points of contribution from the LDR Holding Corporation ... second quarter of 2016, or 0.3% on a constant ...
Breaking Medicine Technology:
(Date:8/22/2017)... (PRWEB) , ... August 22, 2017 , ... “To Walk ... radioman on a B17 bomber named Edward Koontz. “To Walk Away” is the creation ... Scranton, who has published over two hundred manuscripts in chemistry and religion, as well ...
(Date:8/22/2017)... ... ... “Glimpses Of Light”: is a unique and thought inspiring guide toward self-discovery and ... author, J.M. Shepherd, a writer, teacher, traveler, and metaphysician, the author has spent most ... “Love is one of the least understood and yet most sought-after pleasures known to ...
(Date:8/22/2017)... ... August 22, 2017 , ... Although Labor Day is ... many communities have begun providing weekend displays, and numerous households celebrate the unofficial end ... can be downright terrifying for pets. , Kris Zambo, owner of Dynamite ...
(Date:8/21/2017)... Los Angeles, California (PRWEB) , ... August 21, ... ... Physicians is announcing the addition of two plastic surgery fellows for academic year ... is designed for candidates who have successfully completed residency in Plastic and Reconstructive ...
(Date:8/21/2017)... Milwaukee, WI (PRWEB) , ... August 21, 2017 ... ... recent years, with events taking place all over the country. , Outdoor running ... that marathon runners are at an increased risk of melanoma, and only half ...
Breaking Medicine News(10 mins):